THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, August 13, 2026
Oral dissolvable strip technology solutions are gaining stronger relevance as pharmaceutical companies look for dosage formats that are easier to take, faster to administer and better suited to patients who struggle with tablets. The category is moving from novelty to a practical drug-delivery option for selected therapies where convenience and adherence matter.
The oral thin films market is expanding steadily. Mordor Intelligence estimates the market at USD 3.61 billion in 2026 and projects it to reach USD 5.64 billion by 2031, with a CAGR of 9.35 percent. Major companies in the market include ZIM Laboratories, Aquestive Therapeutics, IntelGenx, C.L.Pharm and CURE Pharmaceutical.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The format’s appeal is straightforward. A thin polymer-based film can dissolve on the tongue or inside the mouth without water. This makes it useful for pediatric patients, older adults and people with swallowing difficulty. It can also support discreet administration in settings where carrying bottles or taking tablets may be inconvenient.
Recent pharmaceutical literature describes orodispersible films as patient-friendly systems that disintegrate rapidly in saliva and eliminate the need for swallowing or water. The same review notes advantages for patients with dysphagia or poor treatment adherence, while pointing to formulation advances in polymers, nanocarriers and taste-masking technologies.
For pharmaceutical companies, the business case depends on product fit. Oral strips may be useful for drugs that need rapid administration, improved patient compliance or a differentiated lifecycle strategy. They may also help companies reformulate existing medicines in a way that improves usability without changing the core therapeutic objective.
The market is also supported by broader demand for non-invasive drug delivery. The Business Research Company says the oral thin films market will grow from USD 4.99 billion in 2025 to USD 5.72 billion in 2026, citing preference for non-invasive delivery, psychiatric and neurological treatment expansion, fast-acting therapies and improvements in film manufacturing.
Technology providers must still manage formulation limits. Not every drug is suitable for a strip. Dose size, taste, solubility, stability and absorption behavior can affect whether a candidate can be developed successfully. A strip that dissolves well but cannot deliver the required dose will not meet clinical needs.
Manufacturing reliability is equally important. Film thickness, drug uniformity and packaging stability must be controlled carefully. Any variation can affect dosing or shelf life. Providers that can support formulation development, scale-up and quality control will stand out.
The next phase of oral strip adoption will likely favor companies that combine patient-centered design with pharmaceutical rigor. Convenience alone is not enough. The product must be stable, manufacturable and clinically appropriate.
Oral dissolvable strip technology solutions are becoming a meaningful option in drug-delivery strategy. Their value will be measured by whether they help companies improve usability while preserving dose accuracy, safety and therapeutic performance.
More in News